MedTrace Logo

Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00002756 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2014-02-14

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them as induction intensification may kill more cancer cells.

PURPOSE: This phase II trial is studying how well induction intensification works in treating infants with newly diagnosed acute lymphocytic leukemia.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

asparaginase

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

DRUG

etoposide

DRUG

leucovorin calcium

DRUG

mercaptopurine

DRUG

methotrexate

DRUG

prednisone

DRUG

therapeutic hydrocortisone

DRUG

vincristine sulfate

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Zoann E. Dreyer, MD · Texas Children's Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-06-30
Primary Completion
2007-09-30
Completion
2012-03-31

Countries

  • United States
  • Australia
  • Canada
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002756 on ClinicalTrials.gov